RS61760B1 - Režimi doziranja amisulprida za lečenje mučnine i povraćanja - Google Patents

Režimi doziranja amisulprida za lečenje mučnine i povraćanja

Info

Publication number
RS61760B1
RS61760B1 RS20210407A RSP20210407A RS61760B1 RS 61760 B1 RS61760 B1 RS 61760B1 RS 20210407 A RS20210407 A RS 20210407A RS P20210407 A RSP20210407 A RS P20210407A RS 61760 B1 RS61760 B1 RS 61760B1
Authority
RS
Serbia
Prior art keywords
amisulpride
antiemetic
injectable
phase
kit
Prior art date
Application number
RS20210407A
Other languages
English (en)
Serbian (sr)
Inventor
Julian Clive Gilbert
Robert William Gristwood
Gabriel Fox
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of RS61760B1 publication Critical patent/RS61760B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RS20210407A 2015-04-10 2016-04-11 Režimi doziranja amisulprida za lečenje mučnine i povraćanja RS61760B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506116.1A GB201506116D0 (en) 2015-04-10 2015-04-10 Kit and combination therapy for nausea and vomiting
PCT/GB2016/050998 WO2016162695A1 (en) 2015-04-10 2016-04-11 Combinations of amisulpride and another anti-emetic for treating nausea and vomiting
EP16716659.4A EP3280392B1 (en) 2015-04-10 2016-04-11 Dosage regimens of amisulpride for treating nausea and vomiting

Publications (1)

Publication Number Publication Date
RS61760B1 true RS61760B1 (sr) 2021-05-31

Family

ID=53333601

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210407A RS61760B1 (sr) 2015-04-10 2016-04-11 Režimi doziranja amisulprida za lečenje mučnine i povraćanja

Country Status (22)

Country Link
US (1) US10322106B2 (enExample)
EP (1) EP3280392B1 (enExample)
JP (1) JP6812360B2 (enExample)
KR (2) KR20240125705A (enExample)
CN (1) CN107872975A (enExample)
AU (1) AU2016246104B2 (enExample)
CA (1) CA2982251C (enExample)
CY (1) CY1124184T1 (enExample)
DK (1) DK3280392T3 (enExample)
ES (1) ES2866933T3 (enExample)
GB (1) GB201506116D0 (enExample)
HR (1) HRP20210624T1 (enExample)
HU (1) HUE054165T2 (enExample)
IL (2) IL295650A (enExample)
LT (1) LT3280392T (enExample)
MX (1) MX388735B (enExample)
PL (1) PL3280392T3 (enExample)
PT (1) PT3280392T (enExample)
RS (1) RS61760B1 (enExample)
SI (1) SI3280392T1 (enExample)
SM (1) SMT202100216T1 (enExample)
WO (1) WO2016162695A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN118593482A (zh) 2017-12-05 2024-09-06 赛诺维信制药公司 非外消旋混合物及其用途
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
EP4496797A1 (en) 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4508047A1 (en) 2022-04-14 2025-02-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN120693338A (zh) 2022-12-22 2025-09-23 加舒布鲁姆生物公司 杂环的glp-1激动剂
IL322686A (en) 2023-02-16 2025-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
US20250019389A1 (en) 2023-06-30 2025-01-16 Gasherbrum Bio, Inc. Heterocyclic agonists
TW202521528A (zh) 2023-07-13 2025-06-01 美商雅空嘉閣生物公司 化合物、組合物及方法
AR133241A1 (es) 2023-07-13 2025-09-10 Aconcagua Bio Inc Compuestos, composiciones y métodos
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201003962D0 (en) 2010-03-10 2010-04-21 Tangentix Ltd Multimedia content delivery system
GB201004020D0 (en) * 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
US20150018360A1 (en) * 2011-09-13 2015-01-15 Biomed Valley Discoveries, Inc. Compositions and methods for treating metabolic disorders

Also Published As

Publication number Publication date
DK3280392T3 (da) 2021-03-08
MX388735B (es) 2025-03-20
CA2982251C (en) 2023-06-13
EP3280392A1 (en) 2018-02-14
IL295650A (en) 2022-10-01
KR102711661B1 (ko) 2024-10-02
KR20180016350A (ko) 2018-02-14
US10322106B2 (en) 2019-06-18
WO2016162695A1 (en) 2016-10-13
IL254929A0 (en) 2017-12-31
AU2016246104A1 (en) 2017-11-30
GB201506116D0 (en) 2015-05-27
US20180071249A1 (en) 2018-03-15
JP2018510898A (ja) 2018-04-19
JP6812360B2 (ja) 2021-01-13
MX2017012991A (es) 2018-02-01
PT3280392T (pt) 2021-03-12
CY1124184T1 (el) 2022-07-22
PL3280392T3 (pl) 2021-10-18
LT3280392T (lt) 2021-04-26
HUE054165T2 (hu) 2021-08-30
AU2016246104B2 (en) 2018-12-13
KR20240125705A (ko) 2024-08-19
EP3280392B1 (en) 2021-02-24
SI3280392T1 (sl) 2021-08-31
HK1250913A1 (en) 2019-01-18
CA2982251A1 (en) 2016-10-13
CN107872975A (zh) 2018-04-03
ES2866933T3 (es) 2021-10-20
HRP20210624T1 (hr) 2021-05-28
SMT202100216T1 (it) 2021-05-07

Similar Documents

Publication Publication Date Title
RS61760B1 (sr) Režimi doziranja amisulprida za lečenje mučnine i povraćanja
ES2623503T3 (es) Composiciones para tratar náuseas y vómitos mediados centralmente
KR101738201B1 (ko) 구토방지제로서의 아미설프라이드의 용도
JP2011140521A (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
WO2008070795A2 (en) Combination therapy using low-dose doxepin for the improvement of sleep
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
JP2015511213A (ja) 薬物送達技術
JP2020506209A (ja) 術後悪心嘔吐の救急治療
JP2012500248A (ja) 不安障害の治療
JP3521143B2 (ja) グラニセトロンおよびデキサメタゾン含有の医薬組成物
RS55436B1 (sr) Upotreba pidotimoda za lečenje psorijaze
TW201806599A (zh) 用於快速開始抗抑鬱作用之給藥方案
HK1250913B (en) Dosage regimens of amisulpride for treating nausea and vomiting
JPS6058726B2 (ja) プリン誘導体を有効成分として含有する抗アレルギ−,鎮痛,鎮静剤
JP2006028144A (ja) 末梢血行障害による不定愁訴の治療剤